Indication

As monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after:
Alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or Crizotinib and at least one other ALK TKI.

Medicine details

Medicine name:
lorlatinib (Lorviqua)
SMC ID:
SMC2239
Pharmaceutical company
Pfizer Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
09 March 2020
SMC meeting date:
04 February 2020
Patient group submission deadline:
02 December 2019